Company profile
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc.

Pipeline24 assets

  • NucresiranRNAi therapeutic / Transthyretin Amyloidosis (TTR)
    ATTR Amyloidosis with CardiomyopathyPhase 3hATTR Amyloidosis with PolyneuropathyPhase 3
  • ZilebesiranRNAi therapeutic / Cardiovascular
    HypertensionPhase 3REVERSIR HypertensionPhase 1
  • RapirosiranALN-HSD / HSD / RNAi therapeutic / Metabolic
    Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2
  • ALN-ANG3ALN-ANG3 / ANG3 / RNAi therapeutic / Metabolic
    Diabetic Kidney DiseasePhase 2
  • ALN-4324ALN-4324 / GRB14 / RNAi therapeutic / Metabolic
    Type 2 Diabetes MellitusPhase 1
  • ALN-2232ALN-2232 / ACVR1C / RNAi therapeutic / Metabolic
    Obesity & Weight ManagementPhase 1
  • ALN-PNPALN-PNP / PNP / RNAi therapeutic / Metabolic
    Non-Alcoholic Fatty Liver Disease (NAFLD)Phase 1
  • ALN-APOC3ALN-APOC3 / APOC3 / RNAi therapeutic / Metabolic
    DyslipidemiaPhase 1
  • ALN-CIDEBALN-CIDEB / CIDEB / RNAi therapeutic / Metabolic
    Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 1
  • Cemdisiran(+/- Pozelimab)RNAi therapeutic / Neuroscience/Other
    Myasthenia GravisPhase 3Geographic AtrophyPhase 3
  • MivelsiranALN-APP / APP / RNAi therapeutic / Neuroscience
    Cerebral Amyloid Angiopathy (CAA)Phase 2Alzheimer’s DiseasePhase 1
  • ALN-HTT02ALN-HTT02 / HTT / RNAi therapeutic / Neuroscience
    Huntington’s DiseasePhase 1
  • ALN-5288ALN-5288 / MAPT / RNAi therapeutic / Neuroscience
    Alzheimer’s DiseasePhase 1
  • ALN-SODALN-SOD / SOD1 / RNAi therapeutic / Neuroscience
    SOD1 Amyotrophic Lateral Sclerosis (ALS)Phase 1
  • ALN-SNCAALN-SNCA / SNCA / RNAi therapeutic / Neuroscience
    Parkinson’s DiseasePhase 1
  • Cemdisiran (+Pozelimab)RNAi therapeutic / Hematology
    Paroxysmal Nocturnal HemoglobinuriaPhase 3
  • ALN-6400ALN-6400 / PLG / RNAi therapeutic / Hematology
    Bleeding DisordersPhase 2
  • AG-236ALN-TMP / TMP / RNAi therapeutic / Hematology
    Polycythemia VeraPhase 1
  • ALN-CFBALN-CFB / CFB / RNAi therapeutic / Hematology
    Paroxysmal Nocturnal HemoglobinuriaPhase 1
  • Elebsiran (+Tobevibart)RNAi therapeutic / Other
    Hepatitis D Virus InfectionPhase 2
  • ALN-BCATALN-BCAT / BCAT / RNAi therapeutic / Other
    Hepatocellular CarcinomaPhase 1
  • ALN-4285ALN-4285 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1
  • ALN-4915ALN-4915 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1
  • ALN-F1202ALN-F1202 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1

Latest news12 items

All news

2025 Corporate Responsibility Report

2025 Corporate Responsibility Report ozaki Mon, 18 May 2026 - 18:42 LEARN MORE › 2025 Corporate Responsibility Report Alnylam's 2025 report details our progress against our corporate responsibility goals Our News 11 news-letter alnylam-2030 top-alinged cr-slide

Alnylam Publishes 2025 Annual Report

Alnylam Publishes 2025 Annual Report ozaki Tue, 7 Apr 2026 - 14:10 LEARN MORE › Alnylam Publishes 2025 Annual Report CEO Yvonne Greenstreet reflects on a transformational year. Our News 12 news-letter alnylam-2030 top-alinged

Alnylam named a Fast Co. Most Innovative Company

Alnylam named a Fast Co. Most Innovative Company ozaki Tue, 31 Mar 2026 - 21:02 Learn More › Alnylam named a Fast Co. Most Innovative Company Third time being recognized by Fast Company Our Science Green dna 13 fast-company top-alinged

Alnylam 2030 Strategy Announced

Alnylam 2030 Strategy Announced ozaki Tue, 3 Feb 2026 - 17:04 Learn More › Alnylam 2030 Strategy Announced Details of our next 5-year strategy shared at JP Morgan Healthcare Conference Our News 14 news-letter alnylam-2030 top-alinged

11 Insights from 11 Years on the List

11 Insights from 11 Years on the List ozaki Tue, 13 Jan 2026 - 19:07 Learn More › 11 Insights from 11 Years on the List What The Boston Globe Top Place to Work survey reveals about our success Our News 17 from11-year qfitlia top-alinged

Alnylam Pharmaceuticals, Inc. • Endpoint Arena